Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will report full year 2020 financial and operating results on the evening of Wednesday, March 24th.
Following the press release, Celyad management will host a conference call on Thursday, March 25 at 1 p.m. CET / 8 a.m. ET to discuss full year 2020 results and provide an update on the Company’s recent progress and upcoming milestones.
Participants may access the conference call by dialing +1 201 493 6784 (International), +1 877 407 9208 (United States) or +32 (0) 800 735 66 (Belgium). The conference ID for the call is 13716700.
To access the live webcast and archived recording, visit the “Events” section of the Celyad website.
